CYP2J6 Inhibitors

Inhibitors targeting CYP2J6 are molecules designed to affect the enzyme's catalytic function by various mechanisms. Most direct inhibitors, like Ketoconazole and Miconazole, interfere with the heme moiety that is vital for CYP2J6's enzymatic function. These inhibitors obstruct substrate binding and reduce the enzyme's capacity to catalyze substrate molecules. Similarly, molecules like Quercetin and Resveratrol also serve as direct inhibitors but utilize different inhibition techniques such as competitive or non-competitive binding to the active site. On the other hand, Bergamottin operates via mechanism-based inactivation to irreversibly alter the enzyme, thereby permanently impeding its functionality.

Calcium channel blockers like Diltiazem and Nifedipine represent a different class of inhibitors, targeting the calcium-dependent regulatory mechanisms of CYP2J6. By suppressing intracellular calcium levels, they modulate the enzyme's function indirectly, since intracellular calcium is critical for enzyme activation. Another layer of complexity is added by inhibitors that act on other enzymes but consequently influence CYP2J6 activity. Fluconazole and Troleandomycin, for example, preferentially inhibit CYP3A4, thus reducing metabolic competition for CYP2J6 substrates. These inhibitors illustrate how the biochemical landscape of a cell can be subtly yet effectively manipulated to control the function of specific enzymes like CYP2J6.